Evidence map›Paper›PMID 36619635›Full record

ArticleFrontiers in medicine2022

Selected renal cells harbor nephrogenic potential.

Prakash Narayan, Andrew T Bruce, Elias A Rivera, Timothy A Bertram, Deepak Jain

Abstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Prakash NarayanDepartment of Bioprocess Research and Development, ProKidney LLC, Winston-Salem, NC, United States.
Andrew T BruceDepartment of Bioprocess Research and Development, ProKidney LLC, Winston-Salem, NC, United States.
Elias A RiveraDepartment of Bioprocess Research and Development, ProKidney LLC, Winston-Salem, NC, United States.
Timothy A BertramDepartment of Bioprocess Research and Development, ProKidney LLC, Winston-Salem, NC, United States.
Deepak JainDepartment of Bioprocess Research and Development, ProKidney LLC, Winston-Salem, NC, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selected renal cells (SRCs), a renal epithelial cell-enriched platform, are being advanced as an autologous cell-based therapy for the treatment of chronic kidney disease. However, the mechanism underlying its renal reparative and restorative effects remains to be fully elucidated. In this study, we coupled knowledgebase data with empirical findings to demonstrate that genes differentially expressed by SRCs form interactomes within tubules and glomeruli and mediate a suite of renal developmental activities including epithelial cell differentiation, renal vasculature development, and glomerular and nephron development. In culture, SRCs form organoids which self-assemble into tubules in the presence of a scaffold. Implanted into the kidneys of subtotally nephrectomized rats, SRCs are associated with comma- and S-shaped body cell formation and glomerular development, and improvement in renal filtration indices and renal microarchitecture. These data suggest that SRCs harbor nephrogenic potential, which may explain, at least in part, their therapeutic activity.

Indexed as

celldiseaseglomerulikidneynephrogenicorganoidstherapytubules

Identifiers

PMID36619635
PMCPMC9815697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.